Clinical Trial Update: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing obinutuzumab plus CHOP vs rituximab plus CHOP in CD20-positive diffuse large B-cell lymphoma was terminated with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2017-08-17